Promedior

Promedior is a clinical-stage biotechnology and pharmaceutical company. The company is committed to developing targeted therapies and innovative drugs to treat rare fibrotic diseases such as IPF and myelofibrosis (MF). Promedior owns the Pentraxin-2 drug development platform and has developed key candidate drugs such as PRM-151 and PTX-2 based on this platform. PRM-151 demonstrated broad anti-fibrotic activity in preclinical models of diseases including pulmonary fibrosis, MF, acute and chronic kidney disease, and liver fibrosis, and was granted Breakthrough Therapy Designation by the FDA in early 2019.